News & Updates

An implantable tibial neuromodulation (ITNM) therapy results in statistically significant improvements in urge urinary incontinence (UUI), urinary frequency, and urgency symptoms, as shown in the TITAN 2 study. These benefits have been sustained through 12 months, with no serious safety concerns.

In the final analysis of the phase III PROTEUS trial, perioperative apalutamide + androgen deprivation therapy (APA+ADT) improves the curative success of radical prostatectomy (RP) in men with high-risk localized or locally advanced prostate cancer (HR LPC/LAPC).

Circulating tumour DNA (ctDNA) testing after neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) may inform patients with muscle-invasive bladder cancer (MIBC) of their risk for recurrence and allows personalized postoperative management in MIBC, results of the TOMBOLA trial have shown.

Prostate cancer patients treated with enzalutamide plus leuprolide have a higher probability of remaining free of distant metastasis, castration resistance, symptomatic progression, and first symptomatic skeletal event (SSE) at 5 years than those treated with leuprolide alone, as shown by the results of the EMBARK study.